Dogwood Therapeutics, Inc.
DWTX
$5.37
$1.1025.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.23M | 1.77M | 733.70K | 970.40K | 839.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.54M | 2.30M | 1.07M | 1.31M | 1.14M |
| Operating Income | -7.54M | -2.30M | -1.07M | -1.31M | -1.14M |
| Income Before Tax | -7.73M | -2.28M | -1.05M | -1.29M | -1.10M |
| Income Tax Expenses | -500.00 | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.73M | -2.28M | -1.05M | -1.29M | -1.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.73M | -2.28M | -1.05M | -1.29M | -1.10M |
| EBIT | -7.54M | -2.30M | -1.07M | -1.31M | -1.14M |
| EBITDA | -7.54M | -- | -- | -- | -- |
| EPS Basic | -6.29 | -2.05 | -1.15 | -1.68 | -1.43 |
| Normalized Basic EPS | -3.69 | -1.28 | -0.72 | -1.05 | -0.90 |
| EPS Diluted | -6.29 | -2.05 | -1.15 | -1.68 | -1.43 |
| Normalized Diluted EPS | -3.69 | -1.28 | -0.72 | -1.05 | -0.90 |
| Average Basic Shares Outstanding | 1.31M | 1.11M | 916.00K | 770.30K | 770.30K |
| Average Diluted Shares Outstanding | 1.31M | 1.11M | 916.00K | 770.30K | 770.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |